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Abstract
Background: Inflammatory bowel diseases (IBD) refer to a group of inflammatory conditions concerning colon and
small intestine, which cause socially uncomfortable symptoms and often are associated with an increased risk of
colon cancer. IBD are complex disorders, which rely on genetic susceptibility, environmental factors, deregulation
of the immune system, and host relationship with commensal microbiota. The complexity of these pathologies
makes difficult to clearly understand the mechanisms of their onset. Therefore, the study of IBD must be faced
exploiting an integrated and multilevel approach, ranging from genes, transcripts and proteins to pathways altered
in affected tissues, and carefully considering their regulatory mechanisms, which may intervene in the pathology
onset. It is also crucial to have a knowledge base about the symbiotic bacteria that are hosted in the human gut.
To date, much data exist regarding IBD and human commensal bacteria, but this information is sparse in literature
and no free resource provides a homogeneously and rationally integrated view of biomolecular data related to
these pathologies.
Methods: Human genes altered in IBD have been collected from literature, paying particular interest for the
immune system alterations prompted by the interaction with the gut microbiome. This process has been
performed manually to assure the reliability of collected data. Heterogeneous metadata from different sources have
been automatically formatted and integrated in order to enrich information about these altered genes. A user-
friendly web interface has been created for easy access to structured data. Tools such as gene clustering
coefficients, all-pairs shortest paths and pathway lengths calculation have been developed to provide data analysis
support. Moreover, the implemented resource is compliant to the Galaxy framework, allowing the collected data to
be exploited in the context of high throughput bioinformatics analysis.
Results: To fill the lack of a reference resource for ‘omics’ science analysis in the context of IBD, we developed the
IBDsite (available at http://www.itb.cnr.it/ibd), a disease-oriented platform, which collects data related to
biomolecular mechanisms involved in the IBD onset. The resource provides a section devoted to human genes
identified as altered in IBD, which can be queried at different biomolecular levels and visualised in gene-centred
report pages. Furthermore, the system presents information related to the gut microbiota involved in IBD affected
patients. The IBDsite is compliant with all Galaxy installations (in particular, it can be accessed from our custom
version of Galaxy, http://www.itb.cnr.it/galaxy), in order to facilitate high-throughput data integration and to enable
evaluations of the genomic basis of these diseases, complementing the tools embedded in the IBDsite.
Conclusions: Lots of sparse data exist concerning IBD studies, but no on-line resource homogeneously and
rationally integrate and collect them. The IBDsite is an attempt to group available information regarding human
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genes and microbial aspects related to IBD, by means of a multilevel mining tool. Moreover, it constitutes a
knowledge base to filter, annotate and understand new experimental data in order to formulate new scientific
hypotheses, thanks to the possibility of integrating genomics aspects by employing the Galaxy framework.
Discussed use-cases demonstrate that the developed system is useful to infer not trivial knowledge from the
existing widespread data or from novel experiments.
Background
Inflammatory bowel diseases (IBD) are a group of
inflammatory conditions concerning colon and small
intestine, which cause socially uncomfortable gastroin-
testinal symptoms. In particular, Crohn’s Disease (CD)
and Ulcerative Colitis (UC) present the highest inci-
dence in population and are associated with an
increased risk for colon cancer [1].
Understanding the causes of the IBD onset is not tri-
vial, since they are complex polygenetic diseases that
involve the contributions of genetic susceptibility [2]
(collectively, the loci identified to date represent around
15% of the overall variance of potential disease risk, with
a dominant contribution provided by three common
NOD2 variants), environmental factors (i.e. diet, stress,
antibiotics assumption), deregulation of the immune sys-
tem and its relationship with the commensal microbiota.
In particular, the process leading from a controlled
inflammatory condition, caused by the physiological and
irreplaceable presence of microbial flora in the bowel, to
a pathological inflammation is still widely unknown [3].
Recent advances in mapping the genetic basis of dis-
ease susceptibility, coupled with rapid improvements in
characterization of the microbiome in healthy and dis-
eased individuals, offer great hope for the development of
new IBD treatments. Nevertheless, several key issues
need to be better understood. These include, first of all,
the determination of the biomolecular mechanisms
responsible for the pathology onset. Another important
aspect is the capability to distinguish between individual-
ity in IBD aetiology and commonality in pathogenic
effector modules, so that therapies can be tailored appro-
priately to diverse patient subgroups to suitably restore
homeostasis. The influence of microbiome-derived mole-
cules on local and systemic immune responses is another
area of great scientific interest, that seems to be crucial
to determine the way immune system feeds back into
shaping the composition of the microbiome [4].
Due to its complexity, the study of IBD must be faced
exploiting an integrated and multilevel approach, ranging
from genes, transcripts, proteins and pathways altered in
affected tissues and trying to consider the regulatory
mechanisms intervening in the pathology onset, paying
particular attention to the identification of the involved
commensal bacteria. The majority of the data available in
literature about IBD are not organized in a database
structure: some experiments concern genetics, other
resources are related to epidemiological aspects, while
most data are endoscopical and histological information
useful for basic clinical investigations [5,6]. To date,
more than 8000 papers about IBD are reported in
PubMed [7], around 15000 assays on human and animal
models are stored in ArrayExpress [8] and GEO [9], hun-
dreds of NGS experiments can be downloaded from SRA
[10] and ENA [11]. Nevertheless, all of them are sparse
in literature, and no on-line resources have been devel-
oped to homogeneously and rationally integrate biomole-
cular data related to IBD.
Knowledge-base systems are of critical importance for
supporting the formulation and validation of novel
hypotheses relying on available genome wide association
approaches, target re-sequencing experiments, epige-
netics evaluations, RNA-sequencing analysis, proteomics
studies, metagenomics or metatranscriptomics experi-
mental designs.
Our approach was to develop the IBDsite, a disease-
oriented platform, which collects data related to biomole-
cular mechanisms altered in IBD. This site records
human and bacterial information related to CD and UC,
and exploits data integration strategies and analysis tools
to help inferring not trivial knowledge from the existing
widespread data or for analysing novel experimental data.
The IBDsite is freely available at the URL http://www.itb.
cnr.it/ibd. The infrastructure is also compliant with the
Galaxy platform [12], as it can be experimented using
our local instance of the Galaxy (freely available at the
URL http://www.itb.cnr.it/galaxy), which presents the
IBDsite among the list of data sources, thus promoting
analysis on IBD related genomic high-throughput users’
data.
The IBDsite aims at representing a first attempt to
knowledge and discovery integration of IBD biomolecu-
lar aspects by collecting human genes involved in IBD
(and providing a hierarchical annotation of the samples)
together with data about the involved commensal bac-
teria. To our knowledge, this represents an important
and innovative reference in this field. On the other
hand, the presented platform enables the integration
with the Galaxy system, thus promoting the analysis of
novel genomic experimental data (i.e. sequencing and
microarray) in the perspective of enhancing the knowl-
edge about IBD.
Merelli et al. BMC Bioinformatics 2012, 13(Suppl 14):S5
http://www.biomedcentral.com/1471-2105/13/S14/S5
Page 2 of 14
Methods
The IBDsite relies on the MySQL database management
system for data maintenance, which enables collecting
and formatting heterogeneous data from different
sources, in order to make them accessible to the scientific
community through a unified query schema by means of
a web interface (Figure 1). Information is structured
according to a gene-centric view, which means that the
central table of the database contains PubMed references
associating specific human genes to IBD. Annotation
tables are related to the main one according to the gene
identifiers, which are also used for structuring the
ontology support and the systems biology layer. Even
concerning commensal bacteria, the main table maintains
data from literature and reports PubMed identifiers of
scientific papers associating specific bacteria with the
pathology and the related altered mechanisms. Whenever
possible, a direct correlation is made between human
genes and bacterial species causing the dysbiosis. A table
dedicated to taxonomy information (retrieved from the
NCBI Taxonomy [13]) has been populated for a better
characterization of disease-involved bacteria.
The primary data collection about genes involved in
IBD has been performed manually from literature,
Figure 1 The IBDsite data schema. Conceptual schema of the information content maintained in IBDsite. Data about H. sapiens genes that
correlate to IBD are structured according to a gene-centric view. Annotation tables are related to the main one according to the gene
identifiers, also used for structuring the ontology support and the systems biology layer. For commensal bacteria knowledge, the main table
maintains data from literature, associating specific bacteria with the pathology and alteration mechanisms.
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which in the authors’ opinion is an added value of the
implemented database, since it guarantees a high relia-
bility of the resource. This manual process will be per-
formed periodically, according to novel papers published
in this field.
Annotation data have been retrieved from diverse
resources, differently formatted and organized, that
includes: Gene Ontology [14] for stardardized gene pro-
ducts annotation terms; RefSeq [15] for sequence data;
Entrez Gene [16] for gene annotation; Uniprot [17] and
Protein Data Bank (PDB) [18] for protein annotation
and structure; InterPro [19] for what concerns protein
domains; Biogrid [20] for proteins interections; KEGG
[21] and Reactome [22] for pathways data. Gene Expres-
sion Atlas [8] has been queried for retrieving transcrip-
tion profiles while MyMir [23] for retrieving predictions
about miRNA-targets relation. The database considered
as primary source for sequences concerning metage-
nomics and metatranscriptomics experiments context is
the NCBI Genome/Bacteria database [24].
Different scripts for downloading annotation data
regarding genes involved in IBD were implemented ad
hoc for each resource, in a typical data warehouse fash-
ion. Repositories that enable batch download modes,
such as NCBI maintained databases, have been queried
following standardized approaches (i.e. web services),
while download has been enabled through suitable http
links or ftp sections for resources without direct access to
data. In both cases, the developed system is robust even
in the case of changes to the original resources, since
data are typically provided in structured formats.
Retrieved information was parsed and formatted suitably
to populate the database tables: this enables an easy data
access (through sql query language) and the creation of a
user-friendly interface. Monthly maintenance will be per-
formed by the system developers to keep updated the
IBD repository data. Users will be acknowledged of the
latest updates.
In order to exploit the IBDsite knowledge base for the
analysis of biomolecular high-throughput experiments,
the system was designed to be a source of data for the
Galaxy platform, one of the most popular frameworks for
genomic sequences management, their alignments, and
functional annotation. This integration can be tested in
our local instance of this framework, called Galaxy@ITB,
through which all the examples in the following section
were performed. The IBDsite was inserted among the
data sources of Galaxy@ITB, by defining an XML config-
uration file, which instructs the system in loading the file
provided by the external source. This configuration
allows the user to select a set of genes of interest from
the IBD database and to exploit it as knowledge base for
analysing external datasets such as novel experimental
results or literature datasets from recognised repositories.
Results
The IBDsite
The web interface of the IBDsite (Figure 2) has been
implemented in PHP and JavaScript languages and pro-
vides tools to query, show and analyse data collected in
the resource. Queries on human data can be performed
through gene or protein identifiers, synonyms and descrip-
tions, or information about gene products function, repre-
sented by the protein domains and the GO Molecular
Functions. Moreover, it is possible to query the system
considering the genomic region (spatial coordinates
mapped on the UCSC Genome browser [25]) or the cell
compartment, a feature accomplished by using the GO
Cellular Components annotation. Finally, the IBDsite can
be queried from a specific biochemical pathway name,
exploiting KEGG, Reactome and GO Biological Processes
data: in this context, the user interested in a specific biolo-
gical process can retrieve the list of genes found involved
in IBD.
For each human gene known to be involved in IBD a
report is available. IBD genes are annotated by gene sym-
bol, description, aliases, sequences and related molecular
alterations with reference to the papers where are
described. Collected evidence concerns genomic variations
such as Single Nucleotide Polymorphisms (SNPs) occur-
ring in genes and their flanking regions, gene expression
level, and transcription and translation regulation factors.
Gene expression information is supported by a link
towards the Gene Expression Atlas [8] report page, where
the over/under expression of the specific gene in CD and
UC is listed. Each gene is also associated with microRNAs
that are predicted to target the gene transcripts, as
retrieved from myMIR site. Gene products have been col-
lected as lists of mRNA sequences and related protein iso-
forms according to the NCBI RefSeq. They are annotated
with all the identifiers suitable to download the related
sequences, with functional domains according to InterPro
and structural models from the PDB. Furthermore, the
IBDsite retrieves information regarding biochemical net-
works where the gene is involved as reported in KEGG
and Reactome and the protein-protein interactions (PPIs)
annotated in BioGRID.
The immunological aspect of the IBD onset must be
evaluated in the perspective of patients’ microbiome
composition. Therefore, it is crucial to consider the pre-
sence (and the quantity) of commensal bacteria, which
are known to deregulate the immune system in UC and
CD. A whole section of the IBDsite is dedicated to the
microbiome members involved in these pathologies.
Data about bacteria can be accessed through the ‘Bac-
teria’ link in the left menu, where user can query the
IBD involved bacteria and the human genes altered in
disbiosys. The bacteria report lists the bacterial taxon-
omy information together with the reference papers
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about their involvement in the considered pathologies,
and the correlated altered human genes, if known: in
the latter case both these data are also visualized on the
genes report page, thus providing a complete overview
of the host/commensal relationship.
Galaxy interaction
IBDsite data can be accessed through the Galaxy plat-
form, in particular, considering the Galaxy@ITB
instance of this framework, by clicking on the suitable
link listed under GetData section (left menu). The inter-
action between the IBDsite and Galaxy allows to import
information that enable the analysis of novel data in the
light of the IBDsite knowledge content. Genomics data
can be uploaded in the system either from the local file
system or by downloading them directly from standar-
dized remote repositories of high-throughput biomole-
cular data, such as SRA for short read sequences, or
GEO and ArrayExpress for gene expression microarrays.
This is possible in Galaxy@ITB by employing custo-
mized Galaxy tools (i.e. the genebank plugin and the
Rgenetics package).
This integration strategy is oriented to H. sapiens
genes and gut bacteria genomics data, with particular
concern to next generation sequencing data, both for
DNA and RNA sequences, genotyping data, and gene
expression microarrays.
The procedure for sequences analysis consists in differ-
ent pipelines of semi-standardized steps, provided by the
Galaxy framework and customizable for specific require-
ments. Generally, these steps include data quality evalua-
tion, sequence trimming, data mapping on human and
bacteria genomes, differential expression evaluation, and
phylogenetic analysis. Relying on the features enabled by
Galaxy@ITB, reads can be visualized on many different
genome browsers (UCSC Genome Browser [25], Ensembl
Figure 2 IBDsite features. Examples of features of the IBDsite integrated with the Galaxy@ITB framework. A) Through the IBDsite link in the ‘Get
Data’ list the maintained data are accessible in the Galaxy platform. B) The menu on the left of the site allows to browse the information (the
Search button provides query masks). C) The retrieved list of data can be sent to the Galaxy framework and appear, as usual, on the right side,
where data can be chosen to perform desired analysis.
Merelli et al. BMC Bioinformatics 2012, 13(Suppl 14):S5
http://www.biomedcentral.com/1471-2105/13/S14/S5
Page 5 of 14
[26], GBrowse [27], GeneTrack [28], Trackster [29]), thus
allowing the evaluation of genetic alterations (in case of
DNA sequences), or modulations in gene expression (in
case of RNA alignments). Both IBDsite data and Galax-
y@ITB information refer to the hg19 (GRCh37) release
of the human genome, thus being comparable and dis-
playable on the same genome track. Therefore, the whole
set of IBD genes maintained in the IBDsite can be visua-
lized with experimental data in the Galaxy@ITB frame-
work, supporting the analysis of the alterations found in
inflammatory bowel pathologies. Alternatively, IBDsite
data can be filtered before mapping (i.e. on the basis of a
specific biochemical pathway, or a cellular localization or
even a chromosomal position) thus providing a diverse
perspective of the analysed data.
Discussion
In this section we will describe the use of the IBDsite in
the context of some typical Galaxy based analysis. The sys-
tem, in the version integrated into Galaxy@ITB, has been
used to perform analysis on publicly available literature
data of gene expression microarray, metagenomics experi-
ments and RNA-sequences.
Genome wide analysis microarray
We exploited data produced in a genome-wide expres-
sion study on 36 human samples, performed at the John
Hopkins School of Medicine [30]. Here single endoscopic
pinch biopsies were used to elucidate patterns of gene
expression in active and inactive areas of UC and CD,
even considering indeterminate colitis (IC) and infectious
colitis (IF), in order to identify pathogenic processes
underlying these disease subtypes. Experiments have
been performed using Affymetrix ‘Human Genome U95
Version 2’ chips. Unsupervised classification of different
biopsies suggested that diverse sample types present dis-
tinctive expression patterns. The most important results
concern the identification of differentially expressed
genes (DEGs) in CD vs. normal samples (mainly IFITM1,
IFITM3, STAT1, STAT3, TAP1, PSME2, and PSMB8),
and in UC vs. normal conditions (mainly HNF4G, KLF5,
AQP8, ATP2B1, and SLC16A).
By employing a customized version of the Rgenetics plu-
gin of Galaxy [31], microarray raw data have been
retrieved from the GEO repository (identifier: GSE6731)
and processed with different R-Bioconductor tools inte-
grated within our Galaxy@ITB framework, in order to
define the differentially expressed genes. Data have been
normalized with two main methods, MAS5 [32] and RMA
[33], calculating both the p-value and the fold change of
the microarray results. Parameters employed for these
analyses (respectively: p-value < 0.002 and absolute value
of fold-change > 2) have been defined in order to point out
real differences in the gene expression of affected and
unaffected patients. Although the original analysis was
performed with a different pipeline (relying on DChip [34]
and SAM [35]), results present a considerable overlap
both for CD and UC.
The added value provided by the IBDsite integration to
these analyses is the possibility to reconsider data in the
view of our knowledge base, by evaluating for example
only specific pathways or biological processes involved in
IBD. The whole perspective of the analysis can be
reverted, by mapping expression of genes belonging to
specific networks (working also below the given thresh-
old), instead of inferring annotation only of differentially
expressed genes (like it is common to proceed).
Concerning biomolecular pathways and biological pro-
cesses, the IBDsite can show genes involved in specific net-
works related to IBD. Dataset transmitted to Galaxy@ITB
reports genes included into specific pathways: those altered
in IBD are labelled and can be visualized as separate sub-
sets. For example, we intersected the DEGs related to
microarray data, achieved using fold change values calcu-
lated with the MAS5 algorithm, with genes of different
pathways. Results are reported in Table 1. The table shows
that the correlation of the IBD onset with the immune sys-
tem pathway, although largely expected, comes out clearly
when genes of this pathway are used to filter DEGs.
Data can be visualized in one of the genomic browsers
available at Galaxy@ITB together with data extracted
from the IBDsite, considering, for example, the whole
set of genes maintained in the database and the subset
related to the immune system. An example of data
visualization is reported in Figure 3A, related to human
chromosome 1 (also accessible at http://www.itb.cnr.it/
sup/ibd/v/colon-microarray).
The immediate and complete vision provided by this
integrative visualization on the whole genome allows a
clear overview of the involvement of genomic regions in
the pathology onset. For example, the chromosome 1
appears as one of the most involved in the four consid-
ered diseases (UC, CD, IC, IF), as it can be inferred by
the correlation among DEGs found in the four pathol-
ogy subgroups and the knowledge retrieved from the
IBDsite. The possibility to visually integrate this infor-
mation permits, for example, to recognise region
chr1:140,000,000-170,000,000 (Figure 3B), as crucial for
the IBD onset. Actually, this chromosomal localization
includes many genes known as involved in these pathol-
ogies, such as MUC1 [36], CD48 [37], FASLG [38],
ECM1 [39] and IL6R [40].
The full set of data and analysis steps used for this
use-case are accessible at Galaxy@ITB in the Published
History under the name ‘Colon Microarray’ (available at
url: http://www.itb.cnr.it/sup/ibd/h/colon-microarray).
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Metagenomics of the microbiome
The second application example has been performed on
metagenomics sequencing data, downloaded from the
SRA archive. The considered experiment (identifier:
SRP002427) describes the gut microbiome of different
patients affected by UC, coming from gut biopsies col-
lected in the frame of the multi-center Ulcerative Colitis
Human Microbiome Project (UCHMP), which aims at
examining the role of the enteric microbiome in causing
human ulcerative colitis.
Starting from the hypothesis that changes in micro-
biota will precede the onset of IBD, the main target of
the study is to determine the role of the gut bacteria in
the development of human inflammatory bowel disease
using the whole metagenome sequencing technique. The
microbial profile of the inflamed area will lead the choice
of the most effective antibiotic therapy. Human tissue
components have been removed from the samples, thus
the aligned sequences should refer only to the bacterial
components of the bowel. Data have been locally
Table 1 Functional annotation of expression microarray.
Immune System Cytokine interaction Inflammatory response Apoptosis (GO term)
UC (297) 22 14 12 4
CD (77) 15 16 12 2
IF (353) 16 10 14 4
IC (1226) 30 20 13 15
Number of Differential Expressed Genes (DEGs) involved in diverse pathways for different IBD (UC: Ulcerative Disease, CD: Crohn’s Disease, IF: infectious colitis, IC:
Indeterminate colitis). The total number of DEGs is reported in brackets.
Figure 3 Examples of differential expression genes in microarray data on Galaxy. A) Colon microarray data mapped on Chromosome 1. B)
Focus on the Chromosome 1 region 135,166,038-186,353,811 that appears to be rich of differentially expressed genes corresponding with genes
involved in IBD.
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downloaded and analysed using a Galaxy workflow,
which mainly relies on the annotation of sequences using
Megablast [41] against the Whole Genome Shotgun
sequence assemblies (WGS) database [42]. The annota-
tion results are then analysed through a set of parsers for
the identification of the sequences taxonomy, relying on
the data fetched from the Taxonomy database available
at NCBI, and the creation of a phylogenetic tree.
Using Galaxy@ITB, two samples of commensal bac-
teria from UC patients (identifier: SRR059128 and
SRR059129) have been analysed using the metagenomics
workflow, and results about the obtained phylogenetic
tree are shown in Figure 4. Moreover, in order to com-
pare the number of reads falling in each particular
taxon for the two samples, a Poisson process has been
performed, in order to calculate two Z scores (Z1 [43]
and Z2 [44]). Results are reported in Table 2.
Using the information available in the IBDsite, it is pos-
sible to annotate the phylogenetic tree computed by
Galaxy@ITB in order to correlate information regarding
the identified microbioma alterations and the gene corre-
lated to this disbiosys. In particular, for each leaf of the
phylogenetic dendrogram it is possible, by means of the
IBD site knowledge base, to correlate the pathologies
(and the PubMed identifier of the literature reference),
the experiment type, the sample type, the involved
human genes and additional notes when available. In the
example, this annotation helps in correlating the dis-
biosys with mucosal cytokine and chemokine profiles, in
particular for interleukin-1 beta (IL-1 beta), interleukin-6
(IL-6), interleukin-8 (IL-8) and TNF alpha [45-47].
Data and analysis steps used for this analysis are accessi-
ble at the Galaxy@ITB site in the Published History under
the name ‘Colon Metagenomic’, through the link http://
www.itb.cnr.it/sup/ibd/h/colon-metagenomics.
Analysis of colon RNA sequencing
A last example is within the context of human RNA
sequencing. In this case we chose to consider samples of
patients affected by colon cancer versus normal samples,
Figure 4 Phylogenetic distribution. Phylogenetic distributions of sequences found in the analysed samples of UC affected patient. Colours are
related to the cardinality of the datasets.
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Table 2 Taxonomy distribution over samples
Phylum Readcount1 Readcount2 Z1 Z2
root 207235 210000 4.281 4.281
Archaea 15046 17879 15.613 15.627
Bacteria 161268 152968 14.806 14.808
Eukaryota 30921 39153 31.098 31.152
Fungi 20141 25403 24.657 24.698
Metazoa 6456 8101 13.634 13.656
Viridiplantae 4324 5649 13.268 13.297
Dikarya 20141 25403 24.657 24.698
Actinobacteria 4323 2841 17.509 17.605
Ascomycota 20141 25403 24.657 24.698
Bacteroidetes 89950 79208 26.118 26.131
Chordata 6456 8101 13.634 13.656
Euryarchaeota 15046 17879 15.613 15.627
Firmicutes 42408 46791 14.675 14.680
Fusobacteria 2797 3530 9.215 9.231
Fusobacteria 2797 2947 1.979 1.979
Proteobacteria 21790 20598 5.790 5.790
Streptophyta 4324 5649 13.268 13.297
Craniata 6456 8101 13.634 13.656
Pezizomycotina 7813 9558 13.240 13.257
Saccharomycotina 12328 15845 20.953 20.995
Gnathostomata 6456 8101 13.634 13.656
Bacilli 4234 5129 9.249 9.260
Bacteroidia 8234 6936 10.539 10.548
Betaproteobacteria 6256 5832 3.856 3.857
Clostridia 28095 30316 9.190 9.191
Eurotiomycetes 7813 9558 13.240 13.257
Flavobacteriia 1414 1896 8.378 8.400
Fusobacteria 2455 3530 13.896 13.952
Fusobacteria 2455 2947 6.694 6.701
Gammaproteobacteria 12291 10599 11.183 11.191
Liliopsida 4324 5649 13.268 13.297
Mammalia 6456 8101 13.634 13.656
Methanobacteria 7673 9583 14.540 14.562
Saccharomycetes 12328 15845 20.953 20.995
Thermococci 7373 8296 7.374 7.377
Eurotiomycetidae 7813 9558 13.240 13.257
Commelinids 4324 5649 13.268 13.297
Euarchontoglires 6456 8101 13.634 13.656
Bacteroidales 8234 6936 10.539 10.548
Clostridiales 28095 30316 9.190 9.191
Enterobacteriales 12291 10599 11.183 11.191
Eurotiales 7813 9558 13.240 13.257
Flavobacteriales 1414 1896 8.378 8.400
Fusobacteriales 2455 2947 6.694 6.701
Lactobacillales 4234 5129 9.249 9.260
Methanobacteriales 7673 9583 14.540 14.562
Neisseriales 6256 5832 3.856 3.857
Poales 4324 5649 13.268 13.297
Primates 6456 8101 13.634 13.656
Saccharomycetales 12328 15845 20.953 20.995
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Table 2 Taxonomy distribution over samples (Continued)
Thermococcales 7373 8296 7.374 7.377
Haplorrhini 6456 8101 13.634 13.656
Hominoidea 6456 8101 13.634 13.656
Bacteroidaceae 8234 6936 10.539 10.548
Clostridiaceae 2545 3048 6.726 6.733
Enterobacteriaceae 12291 10599 11.183 11.191
Fusobacteriaceae 2455 2947 6.694 6.701
Hominidae 6456 8101 13.634 13.656
Lachnospiraceae 7272 9245 15.352 15.379
Methanobacteriaceae 7673 9583 14.540 14.562
Neisseriaceae 6256 5832 3.856 3.857
Poaceae 4324 5649 13.268 13.297
Ruminococcaceae 18278 18023 1.338 1.338
Saccharomycetaceae 12328 15845 20.953 20.995
Streptococcaceae 4234 5129 9.249 9.260
Thermococcaceae 7373 8296 7.374 7.377
Trichocomaceae 7813 9558 13.240 13.257
Homininae 6456 8101 13.634 13.656
Pooideae 4324 5649 13.268 13.297
Triticeae 4324 5649 13.268 13.297
Aegilops 4324 5649 13.268 13.297
Bacteroides 8234 6936 10.539 10.548
Buchnera 6526 4039 24.196 24.368
Clostridium 2545 3048 6.726 6.733
Emericella 7813 9558 13.240 13.257
Escherichia 3423 4023 6.953 6.959
Faecalibacterium 8768 7754 7.889 7.892
Fusobacterium 2455 2947 6.694 6.701
Homo 6456 8101 13.634 13.656
Kluyveromyces 6161 7431 10.893 10.905
Methanothermobacter 7673 9583 14.540 14.562
Neisseria 6256 5832 3.856 3.857
Pyrococcus 7373 8296 7.374 7.377
Ruminococcus 9510 10269 5.397 5.398
Saccharomyces 6167 8414 18.608 18.664
Aegilops tauschii 4324 5649 13.268 13.297
Bacteroides thetaiotaomicron 8234 6936 10.539 10.548
Buchnera aphidicola 6526 4039 24.196 24.368
Emericella nidulans 7813 9558 13.240 13.257
Escherichia coli 3423 4023 6.953 6.959
Faecalibacterium prausnitzii 8768 7754 7.889 7.892
Fusobacterium nucleatum 2455 2947 6.694 6.701
Homo sapiens 6456 8101 13.634 13.656
Kluyveromyces lactis 6161 7431 10.893 10.905
Methanothermobacter thermautotrophicus 7673 9583 14.540 14.562
Neisseria gonorrhoeae 6256 5832 3.856 3.857
Pyrococcus horikoshii 7373 8296 7.374 7.377
Ruminococcus gnavus 5255 6709 13.293 13.318
Ruminococcus torques 4255 3560 7.862 7.870
Saccharomyces cerevisiae 6167 8414 18.608 18.664
List of the Z-scores obtained using Poisson distribution on the analysed metagenomics data. This statistical evaluation highlights the correlation between the
reads distribution in the taxonomy found in the samples from patient with UC and CD.
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since no data are available concerning RNA-sequencing
in relation to IBD affected patients. Nevertheless, the
choice is well fitted with the research on IBD, since colon
cancer onset is the most diffuse follow-up of inflamma-
tory bowel diseases. RNA-sequencing data have been
automatically downloaded from the SRA repository at
NCBI using the genebank plugin, available at our local
instance of Galaxy.
In detail, four runs have been downloaded for this
example (normal sample identifiers: SRX066252 and
SRX066254; tumour sample identifiers: SRX066253 and
SRX066255), which describe the expression profile by
high throughput sequencing (Illumina Genome Analyzer)
of human colon cancer and normal samples of two
affected patients. Data have been processed using a well-
established workflow for next generation sequencing
analysis, which mainly relies on the bowtie algorithm
[48], in order to check the quality, filter and align reads
against the reference genome. The pipeline steps are
accessible in the Galaxy@ITB site in the Published His-
tory under the ‘Colon cancer RNA-seq’ identifier (http://
www.itb.cnr.it/sup/ibd/h/colon-cancer).
Mapped results, both tumour affected and normally
affected ones, have been visualized in the same track,
together with the IBDsite data, to present the intersec-
tions among the differentially expressed genes and the
set of genes known to be involved in inflammatory bowel
disorders. Data visualization is available at the following
link http://www.itb.cnr.it/sup/ibd/v/colon-cancer.
Some biologically considerations can be sketched
immediately from these visualized data. An overview of
the whole chromosomes set allows to identify a region
with differential expression among normal and colorec-
tal cancer affected patients: this corresponds to the
SLC26A3 gene, known to be involved in gastrointestinal
pathologies such as congenital chloride diarrhea [49]
and ulcerative colitis [50] (Figure 5A). A similar correla-
tion emerges for DMBT1, which is evidently involved in
ulcerative colitis [51] and in various cancer types (pros-
tate cancer, breast cancer, glioblastoma, medulloblas-
toma and melanoma) and that here appears to be
differentially expressed even among colon cancer and
normal tissues (Figure 5B). Similar considerations can
be done for C15orf48 (chr15: 45722763-45725647),
which results to be differently expressed in cases and
controls and is even known to be involved in gastroin-
testinal disorders [52].
The inflammatory microenvironment related to the
IBD has a prominent role in the onset and progression
of colon cancer, but also a plethora of growth factors
and cytokines are involved in this process. For example,
tumour-necrosis factor-a [53], interleukin-6 [54] and
TGF-b [55] seem to be crucial for tumour initiation,
because they stimulate the inhibition of the NF-B
pathway in epithelial cells. Similarly, data show an
increased expression of the Toll-like receptors, which
stimulated by the gut microflora can directly enhance
tumorigenesis [56].
Combining different ‘omics’ data
Combining different ‘omics’ data, although highly desir-
able, results a difficult task to accomplish, because of
diverse experimental conditions and analysis inhomo-
geneity, which often lead to unmatchable data. An
attempt to overcome this limitation is the use of a bot-
tom-up approach to data, such as that proposed in the
IBDsite. In the IBDsite the layer of manually collected
genes allows to browse and integrate different types of
data: this strategy is made possible by the interaction
with the Galaxy framework, as shown in the previous
discussion. By means of the IBDsite genes, information
provided by IBD microarrays data with RNA-sequencing
data of colon cancer can be combined, to formulate
hypotheses about mechanisms underpinning the patho-
logical inflammatory correlation of these diseases with
colon cancer. Although RNA-sequencing data in
patients affected by IBD would provide more consis-
tency to the description of this process, the analysis per-
formed shows a higher correlation of Ulcerative Colitis
genomic patterns with colon cancer in comparison to
Crohn’s Disease. This aspect clearly emerges in Chro-
mosome 6, Chromosome 10, Chromosome 11, Chromo-
some 12, Chromosome 16, where microarray derived
expression profiles of IC and UC samples resembles the
trend of sequencing data in patients with colon cancer
much more then CD samples (http://www.itb.cnr.it/sup/
ibd/v/micro-cancer). This hypothesis is confirmed by
epidemiologic data that describe a higher risk to develop
colon cancer in patients with UC with respect to CD
[57].
Conclusions
Inflammatory bowel diseases represent a diffuse and dis-
abling class of pathologies, affecting people that
approach their life in a reasonably normal way. Regard-
less the high incidence and a variety of epidemiologic
and genetic studies, causes of the onset and develop-
ment of IBD remain unclear. The sparse and unstruc-
tured knowledge developed in this field neither correctly
support the advances in the development of a pathology
onset model, nor the identification of effective and per-
sonalised therapies for these complex pathologies.
The main targets in the field are the comprehension
of the mechanisms underlying the pathology develop-
ment, the identification of the bacteria involved in the
interactions with the human genome, and the identifica-
tion of the biomolecular hubs where it is possible to
intervene with therapies, especially considering the great
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interindividual variations that can modify the enteric
microbial communities.
The presented work tries to fill the lack of a curated
IBD knowledge base. The IBDsite represents both an
infrastructure to analyse high-throughput experimental
data and an integrated collection of homogeneous
knowledge, that remains crucial for evaluating new
information and to formulate novel scientific hypoth-
eses. The IBDsite maintains, in a structured format, the
available biomolecular knowledge about the human
genes altered in IBD and the bacteria found involved in
their onset, thus acting as a non redundant, consistent
and homogeneous container for CD and UC known bio-
molecular information.
The IBDsite, having the ability of working in connec-
tion with the Galaxy platform, provides a crucial possi-
bility of handling new experimental data and exploiting
the collected knowledge base information, in order to
analyse new samples in the light of the present under-
standing for discerning the multifactorial mechanisms of
the IBD onset.
The proposed infrastructure is capable of handling dif-
ferent types of IBD data and experiments, providing
them the appropriate homogeneity in order to be inte-
grated. The possibility of exploiting data from the IBD-
site in order to correlate different experiments is an
added value to the work: as in all complex pathology,
the collection of data at all ‘omics’ levels is the only
affordable way to achieve a complete vision on the
involved biomolecular mechanisms.
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